Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated interferon alfa-2a to control virological rebound after HAART interruption in chronic HIV infection
2011-004693-29Phase 2Terminated
- Sponsor
- National Institute for Infectious Diseases Lazzaro Spallanzani
- Start
- Mar 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of peginterferon alfa-2a in human immunodeficiency virus infection (HIV), sponsored by National Institute for Infectious Diseases Lazzaro Spallanzani. Primary endpoint: Virologic suppression at week 12 after HAART discontinuation. Started Mar 2012; status: terminated.
02
Drugs
peginterferon alfa-2a
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2011-004693-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004693-29.